日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study

瑞戈非尼联合伊立替康作为转移性胃食管腺癌二线治疗：PRODIGE 58-UCGI35-REGIRI Unicancer 随机 II 期研究结果

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105096
Samalin, E; Evesque, L; Turpin, A; De La Fouchardiere, C; Khemissa-Akouz, F; Bouché, O; Muller, M; Dermeche, S; Botsen, D; Tougeron, D; Zaanan, A; Ben Abdelghani, M; Guardiola, E; Dubreuil, O; Le Brun Ly, V; Hennequin, A; Watson, S; Sefrioui, D; Lecomte, T; De Sousa Carvalho, N; Hulin, A; Crapez, E; Castan, F; Senellart, H
肿瘤
PROD
IGE
肿瘤免疫
发表日期：2025
文献求助 收藏

Towards a better understanding of patient expectations: ONCOPREMs-1 study-a qualitative study

为更好地了解患者期望：ONCOPREMs-1 研究——一项定性研究

期刊:Aging Clinical and Experimental Research
影响因子:3.4
doi:10.1007/s40520-025-03148-8
Diouri, Loubna; Ecarnot, Fiona; Berjot, Sophie; Popiolek, Alexandre; Bouché, Olivier; Botsen, Damien; Lemoine, Amélie; Vignot, Stéphane; Barbe, Coralie
发表日期：2025
文献求助 收藏

Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy

低肌肉量和肌脂肪变性对接受放化疗的不可切除胰腺癌患者的治疗毒性和生存结果的影响

期刊:European Journal of Clinical Nutrition
影响因子:3.3
doi:10.1038/s41430-025-01566-5
Perrier, Marine; Fontaine, Marine; Bertin, Eric; Carlier, Claire; Botsen, Damien; Djelouah, Manel; François, Eric; Guilbert, Philippe; Saint, Angélique; Slimano, Florian; Torielli, Paolo; Brugel, Mathias; Bouché, Olivier
胰腺癌
肿瘤
毒理研究
肿瘤免疫
发表日期：2025
文献求助 收藏

Circulating Exosomal Proteins as New Diagnostic Biomarkers for Colorectal Cancer (EXOSCOL01): A Pilot Case-Controlled Study Focusing on MMP14 Potential.

循环外泌体蛋白作为结直肠癌的新诊断生物标志物（EXOSCOL01）：一项以 MMP14 潜力为重点的试点病例对照研究

期刊:Journal of Clinical Laboratory Analysis
影响因子:2.9
doi:10.1002/jcla.70016
Barhoum Mickaël, Brassart-Pasco Sylvie, Dupont-Deshorgue Aurélie, Thierry Aurore, Kanagaratnam Lukshe, Brassart Bertrand, Ramaholimihaso Fidy, Botsen Damien, Carlier Claire, Brugel Mathias, Perrier Marine, Ramont Laurent, Bouché Olivier
肿瘤
肠癌
外泌体
发表日期：2025
文献求助 收藏

Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted-screening analysis case-control study (PESTIPAC)

胰腺腺癌风险与脂肪组织和尿液中有机氯农药浓度之间的关联：一项靶向筛查分析病例对照研究（PESTIPAC）

期刊:United European Gastroenterology Journal
影响因子:6.7
doi:10.1002/ueg2.12602
Brugel, Mathias; Callon, Sidonie; Carlier, Claire; Amroun, Koceila Lamine; Botsen, Damien; Kianmanesh, Reza; Perrier, Marine; Piardi, Tullio; Renard, Yohann; Rhaiem, Rami; El Balkhi, Souleiman; Bouché, Olivier
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC)

β受体阻滞剂暴露与晚期胰腺导管腺癌患者生存结局：一项回顾性队列研究（BETAPANC）

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2023.1137791
Le Bozec, Antoine; Brugel, Mathias; Djerada, Zoubir; Ayad, Marya; Perrier, Marine; Carlier, Claire; Botsen, Damien; Nazeyrollas, Pierre; Bouché, Olivier; Slimano, Florian
信号转导
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients

在基于尿嘧啶血症的治疗前表型DPD缺乏症筛查中，肾功能损害和肝功能异常的发生率：一项纳入1138例患者的综合性人群研究

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359221148536
Callon, Sidonie; Brugel, Mathias; Botsen, Damien; Royer, Bernard; Slimano, Florian; Feliu, Catherine; Gozalo, Claire; Konecki, Céline; Devie, Bruno; Carlier, Claire; Daire, Viktor; Laurés, Nicolas; Perrier, Marine; Djerada, Zoubir; Bouché, Olivier
发表日期：2023
文献求助 收藏

Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID)

COVID-19 大流行对胰腺腺癌患者疾病分期和治疗的影响：一项法国综合多中心回顾性观察队列研究 (CAPANCOVID)

期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2022.01.040
Brugel, Mathias; Letrillart, Léa; Evrard, Camille; Thierry, Aurore; Tougeron, David; El Amrani, Mehdi; Piessen, Guillaume; Truant, Stéphanie; Turpin, Anthony; d'Engremont, Christelle; Roth, Gaël; Hautefeuille, Vincent; Regimbeau, Jean M; Williet, Nicolas; Schwarz, Lilian; Di Fiore, Frédéric; Borg, Christophe; Doussot, Alexandre; Lambert, Aurélien; Moulin, Valérie; Trelohan, Hélène; Bolliet, Marion; Topolscki, Amalia; Ayav, Ahmet; Lopez, Anthony; Botsen, Damien; Piardi, Tulio; Carlier, Claire; Bouché, Olivier
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis

基于尿嘧啶表型的二氢嘧啶脱氢酶 (DPD) 缺乏症筛查指南对降低 5-氟尿嘧啶类化疗严重副作用的影响：一项暂停评分分析

期刊:Pharmaceutics
影响因子:5.5
doi:10.3390/pharmaceutics14102119
Laures, Nicolas; Konecki, Céline; Brugel, Mathias; Giffard, Anne-Lise; Abdelli, Naceur; Botsen, Damien; Carlier, Claire; Gozalo, Claire; Feliu, Catherine; Slimano, Florian; Djerada, Zoubir; Bouché, Olivier
发表日期：2022
文献求助 收藏

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59

FOLFIRI联合度伐利尤单抗+/-曲美利尤单抗二线治疗晚期胃癌患者的安全性：来自随机II期研究DURIGAST PRODIGE 59的安全性导入期

期刊:Biomedicines
影响因子:3.9
doi:10.3390/biomedicines10051211
Evrard, Camille; Aparicio, Thomas; Soularue, Emilie; Le Malicot, Karine; Desramé, Jérôme; Botsen, Damien; El Hajbi, Farid; Gonzalez, Daniel; Lepage, Come; Bouché, Olivier; Tougeron, David; On Behalf Of The Durigast-Prodige Investigators/Collaborators
胃癌
肿瘤
肿瘤免疫
PROD
IGE
发表日期：2022
文献求助 收藏